Wyeth News

Progenics Pharmaceuticals, Inc. announced its results of operations for the third quarter and nine months ended September 30, 2009.

Less than a month after buying Wyeth, drug giant Pfizer Inc. has mapped out a new structure for its research and development operations.

In a 2005 file photo Richard T. Clark, CEO & President, Merck & Co., speaks during an interview at the corporate headquarters in Whitehouse Station.

Pfizer , fresh from consummating its merger with Wyeth , has unveiled a new logo.

Flamel Technologies today announced that Pfizer has exercised its option to license Flamela s MedusaA technology for the development of a controlled release formulation of an already-marketed therapeutic protein.

Declining sales have pushed Robert McDonald, the new chief executive of US consumer goods giant Procter & Gamble , to look for acquisitions and divestments, The Wall Street Journal writes Thursday citing informed sources.

NEW YORK The approval last week of the Wyeth acquisition by Pfizer marks the return of a consumer-care division to Pfizer, and a considerable one at that.

Progenics Pharmaceuticals ' constipation reliever, Relistor, is a good drug that not enough people want.

Pfizer Inc. today posted a higher third-quarter profit despite the recession, as sharp cost cuts made up for a dip in sales.

Pfizer said Tuesday that it will discontinue Fort Dodge Animal Health 's Overland Park operations, which it took on as part of its acquisition of Wyeth .

Antitrust issues in the U.S. and Canada done, There's nothing left to do. Pfizer wed its bride Wyeth today, And to that I say: "Boo-hoo." The ticker will be gone -- oh WYE? WYE? WYE? Not even a hyphenated name will remain.

Pfizer's offices will be known collectively as "The Leadership Center for Pfizer Diversified Businesses.'' The name reflects the variety of businesses that will be located on the campus, including animal health as well as nutrition and consumer products -- divisions the company gained from Wyeth.

Pfizer Inc. will close Wyeth operations in New Jersey and Pennsylvania and decide what research sites to shut in the next 30 to 60 days, said Chief Financial Officer Frank D'Amelio. Pfizer will keep open Wyeth's Madison corporate headquarters, shutter Wyeth's Bridgewater operations and close two buildings near its main pharmaceutical center in ...

Megamergers in the pharmaceutical industry usually take many months to sort out, but the two research directors at newly combined Pfizer Inc.

Pfizer Inc. said in an internal announcement Wednesday, Oct. 14, that it will close its Bridgewater facility by the middle of 2010 as part of its plans for consolidating with Wyeth, another pharmaceuticals giant that Pfizer has acquired in a $68 billion deal.

Drug makers Pfizer and Wyeth have completed their $68 billion merger. The deal was closed nine months after Pfizer announced the acquisition and one day after the companies got final approval from the Federal Trade Commission and the Canadian Competition Bureau.

Geno Germano said he can't speak for everyone, but he is pleased Pfizer's $68 billion's acquisition of Wyeth is completed and the two companies are now operating as one.

Pfizer Inc. and Merck & Co. are both expected to show the effects of increased competition from generic drugs when the two pharmaceutical bellwethers roll out their third-quarter earnings reports next week.

Wyeth's operations in Great Valley will close next year, but its Collegeville facility will remain open as the result of the pharmaceutical giant's merger yesterday with New York-based Pfizer Inc.

Even as Pfizer Inc. prepared to close its Bridgewater facility by mid-2010 as part of its plans to consolidate with Wyeth, another pharmaceuticals giant, the company also confirmed on Thursday it will keep its bigger operation at the former Beneficial Corp.